Laurus Labs Limited

rs,

tember 12, 2025 To To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 The Listing Department National Stock Exchange of India Ltd., Ex

₹ 5,554

s, 5 Antibody Drug Conjugates © 2025 Laurus Labs Ltd. Investor Presentation | September 2025 3 ₹ 5,554 Cr Revenues FY 2025 20.1% EBITDA Business Division 28%$ CDMO* Contract Development & Manufa

20.1%

© 2025 Laurus Labs Ltd. Investor Presentation | September 2025 3 ₹ 5,554 Cr Revenues FY 2025 20.1% EBITDA Business Division 28%$ CDMO* Contract Development & Manufacturing Services 72% Gene

28%

Presentation | September 2025 3 ₹ 5,554 Cr Revenues FY 2025 20.1% EBITDA Business Division 28%$ CDMO* Contract Development & Manufacturing Services 72% Generics FDF and API $ % to Revenues

72%

25 20.1% EBITDA Business Division 28%$ CDMO* Contract Development & Manufacturing Services 72% Generics FDF and API $ % to Revenues Our Strategy - Customer Centric focus anchored on High qua

rs 7900

r Presentation | September 2025 4 Integrated Large-Scale ‘D & M’ platform to support Global partners 7900 KL Reactors volumes 9 Sites CDMO Activity 1400 Scientists 10 billion Drug Product 240 K

10 billion

o support Global partners 7900 KL Reactors volumes 9 Sites CDMO Activity 1400 Scientists 10 billion Drug Product 240 KL Fermentation R&D center R&D with Kilo lab, Hyderabad DS/DP Development

40%

ble technology and Capability extension Significant Updates >75 R&D projects* supported in FY25 40% Increase in projects on Bio-catalysis platform in FY25 30% Increase in Continuous Flow Reaction p

30%

>75 R&D projects* supported in FY25 40% Increase in projects on Bio-catalysis platform in FY25 30% Increase in Continuous Flow Reaction projects in FY25 • • • • Solidifying position on Flow/Bio

32%

s CAGR % FY 20-25 FY 25 Revenue mix Revenue by Geographical location CDMO GENERICS 1 2 +32% +10% +42% +2% 28% 72% ROW North America Europe ARV revenue share declining & CDMO share m

10%

R % FY 20-25 FY 25 Revenue mix Revenue by Geographical location CDMO GENERICS 1 2 +32% +10% +42% +2% 28% 72% ROW North America Europe ARV revenue share declining & CDMO share more th

42%

20-25 FY 25 Revenue mix Revenue by Geographical location CDMO GENERICS 1 2 +32% +10% +42% +2% 28% 72% ROW North America Europe ARV revenue share declining & CDMO share more than dou